article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

Clinical Pharmacology and Therapeutics. Clinical Pharmacology and Therapeutics. Clarke trained in medicineand immunology at University College London and has had a long-standing interest in the utilisation of biomarker strategies in early clinical development. Rodrigues AD. 113:9861002.

article thumbnail

Altasciences Appoints New General Manager, Clinical Operations

Alta Sciences

“James’ proven leadership skills, and deep knowledge of all phases of clinical research, will be invaluable in delivering expert guidance for our clients along their early-phase clinical journey,” said Ingrid Holmes, Vice President, Clinical Operations, Altasciences.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Altasciences Receives 2024 CRO Leadership Award for Capabilities

Alta Sciences

“For 12 years, Life Science Connect has been working alongside ISR Research to develop our annual CRO Leadership Awards. The Capabilities category assesses respondents on a CRO’s ability to deliver a wide range of services, expertise, and resources across multiple therapeutic areas.

article thumbnail

Biomarker identification in the realm of rare diseases

Drug Target Review

About the author Dr Luke Piggott, Associate Principal Scientist, Debiopharm Luke Piggott possesses extensive experience in developing novel therapeutics, spanning from discovery to clinical trials. At Debiopharm, he has overseen both preclinical and clinical pharmacology of assets from phase I to III.

Disease 59
article thumbnail

A Closer Look At Our On-Site Compounding Pharmacies

Alta Sciences

Adherence to harmonized pharmacy-specific SOPs based on cGMP principles at our three clinical pharmacology units. Clinical Supply Manufacturing Integration with our manufacturing team, ensuring flexibility and adaptability to meet the evolving needs of your studies throughout your drug development program or study.

article thumbnail

Mission Therapeutics Appoints Dr Suhail Nurbhai as Chief Medical Officer

The Pharma Data

Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US. High-resolution images available on request. Photo: Business Wire).

article thumbnail

Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases

The Pharma Data

The research, which spans clinical, health economics and outcomes research, translational, clinical pharmacology and preclinical presentations, highlights the breadth and depth of the company’s data on deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, also because the emerging dermatology pipeline.

Disease 52